NOT APPROVED FOR MEN · EARLY STUDIES
PT-141 for Men: What Early Tests Can Show
Bremelanotide isn't approved for men. This page explains what small erection studies found and why those findings don't prove long-term treatment.
What the early work in men showed and what it could not prove
For men, PT-141 is an unapproved drug studied for erections. FDA approval covers a narrow group of women bothered by lasting low desire before menopause [7].
Men drew interest after erections appeared in early brain-acting drug studies [1]. Those studies were too small and too early to support approval.
A journal warning now covers an older study of male use [10]. This page gives you the sounder findings and the large gaps that remain.
These facts aren't a reason to use the drug. They show you both the early result and its limits.
What changed during the early erection tests
During early tests, PT-141 brought on erections in some men being studied for erection trouble. The response grew as the amount rose, and studies found a similar result in rats and monkeys [1].
Some brain cells linked with sex drive also grew more active. Early nasal-spray tests reached about 7-20 mg and found an erection response above roughly 7 mg [1].
This remains the strongest sound finding in men, but the work was early. It measured brief responses, not long-term care across a large group.
Acting in the brain may help bring on an erection [1]. That finding does not make the drug approved care for men [7].
What the drug changes before blood flow begins
PT-141 begins in brain regions linked with desire and sexual readiness [1]. Blood-flow pills, called PDE-5 drugs, instead help more blood enter the penis.
Because the drugs work differently, reviews have covered PT-141 for sexual trouble in women as well as men [8]. A different approach can deserve study without being proven care.
In women, scans showed higher desire and stronger links between brain regions during sexual pictures [1][5]. Animal work also backs a brain effect.
For men, proof still comes only from small studies comparing several amounts [1]. A sensible idea still needs large trials before you can know it works.
What the disputed study means for claims about men
Safarinejad and Hosseini wrote a 2008 study that received a formal journal warning in 2023. Because it studied men with erection trouble, we don't use its disputed findings [10].
That removes one often-cited claim from the sound evidence. It also makes the gaps in research on men easier to see.
The approved group is limited to some women who still have monthly periods [7]. Early work found that erections grew stronger at larger amounts in men [1].
The drug's brain-first action differs from standard blood-flow pills [1]. That difference deserves study, yet the medicine remains unproven for men [10].
Nausea and the blood-pressure warning still apply to any unapproved use. Read the PT-141 side effects before you weigh the early findings [4][6].
What men report online but trials haven't proved
These are men's personal accounts of unapproved use. Controlled studies didn't gather or test the reports together, so they aren't proof or advice.
Men online often mention warm, red skin in the first hour and nausea soon after. Some describe desire that begins in the mind, not just a physical erection.
Posts also warn that skin may remain dark after frequent use. One person's account can't show how often any effect occurs.
Sound findings in men still come from early work comparing amounts with erection response [1]. Clinical studies and label wording, not posts, provide the side-effect facts [4][6].